The viral clearance market involves products and solutions that are used to detect and remove viruses from biologics such as vaccines and therapeutics. Viral clearance testing helps ensure the safety of biopharmaceutical products by detecting potential viral contamination during the drug development and manufacturing process. It is a crucial step in purification and quality control as even low levels of viral contamination can potentially cause illness or disease transmission. Technologies used in viral clearance include PCR, immune-based assays, and NGS-based assays. Growing demand for biopharmaceuticals and stringent regulatory guidelines mandating viral safety testing of these products are driving increased adoption of viral clearance solutions across the pharmaceutical and biotech industries.

The Viral Clearance Market is estimated to be valued at USD 0.9 Bn in 2024 and is expected to reach USD 1.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 10% from 2024 to 2031.

The growing demand for biopharmaceuticals such as monoclonal antibodies, gene and cell therapies is fueling the Viral Clearance Market. Strict regulations ensure all biologics undergo multiple stages of viral safety testing during development and manufacturing.

Get more insights on: Viral Clearance Market

Get this Report in Japanese Language: ウイルスクリアランス市場

Get this Report in Korean Language: 바이러스 클리어런스 마켓